New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT06975293
First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be enrolled at multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- STC-15 (a METTL3 inhibitor) and toripalimab (an immunotherapy drug)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced cancers and sarcomas that have stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are possible, and the combination therapy may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
-
Northwell Health Cancer Institute
RECRUITINGLake Success, New York, 11042, United States
-
The START Center
RECRUITINGSan Antonio, Texas, 78229, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a new PET tracer reveal a key cancer target?
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a smart drug home in on Hard-to-Treat cancers?